These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

340 related items for PubMed ID: 15837970

  • 1. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer.
    Bander NH, Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ.
    J Clin Oncol; 2005 Jul 20; 23(21):4591-601. PubMed ID: 15837970
    [Abstract] [Full Text] [Related]

  • 2. Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer.
    Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ, Bander NH.
    J Clin Oncol; 2004 Jul 01; 22(13):2522-31. PubMed ID: 15173215
    [Abstract] [Full Text] [Related]

  • 3. Phase 1/2 study of fractionated dose lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (177 Lu-J591) for metastatic castration-resistant prostate cancer.
    Tagawa ST, Vallabhajosula S, Christos PJ, Jhanwar YS, Batra JS, Lam L, Osborne J, Beltran H, Molina AM, Goldsmith SJ, Bander NH, Nanus DM.
    Cancer; 2019 Aug 01; 125(15):2561-2569. PubMed ID: 31012963
    [Abstract] [Full Text] [Related]

  • 4. Pilot Study of Hyperfractionated Dosing of Lutetium-177-Labeled Antiprostate-Specific Membrane Antigen Monoclonal Antibody J591 (177 Lu-J591) for Metastatic Castration-Resistant Prostate Cancer.
    Niaz MJ, Batra JS, Walsh RD, Ramirez-Fort MK, Vallabhajosula S, Jhanwar YS, Molina AM, Nanus DM, Osborne JR, Bander NH, Tagawa ST.
    Oncologist; 2020 Jun 01; 25(6):477-e895. PubMed ID: 31999003
    [Abstract] [Full Text] [Related]

  • 5. Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer.
    Tagawa ST, Milowsky MI, Morris M, Vallabhajosula S, Christos P, Akhtar NH, Osborne J, Goldsmith SJ, Larson S, Taskar NP, Scher HI, Bander NH, Nanus DM.
    Clin Cancer Res; 2013 Sep 15; 19(18):5182-91. PubMed ID: 23714732
    [Abstract] [Full Text] [Related]

  • 6. Phase I trial of docetaxel plus lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (177Lu-J591) for metastatic castration-resistant prostate cancer.
    Batra JS, Niaz MJ, Whang YE, Sheikh A, Thomas C, Christos P, Vallabhajosula S, Jhanwar YS, Molina AM, Nanus DM, Osborne JR, Bander NH, Tagawa ST.
    Urol Oncol; 2020 Nov 15; 38(11):848.e9-848.e16. PubMed ID: 32600929
    [Abstract] [Full Text] [Related]

  • 7. Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen.
    Bander NH, Trabulsi EJ, Kostakoglu L, Yao D, Vallabhajosula S, Smith-Jones P, Joyce MA, Milowsky M, Nanus DM, Goldsmith SJ.
    J Urol; 2003 Nov 15; 170(5):1717-21. PubMed ID: 14532761
    [Abstract] [Full Text] [Related]

  • 8. Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen.
    Vallabhajosula S, Goldsmith SJ, Hamacher KA, Kostakoglu L, Konishi S, Milowski MI, Nanus DM, Bander NH.
    J Nucl Med; 2005 May 15; 46(5):850-8. PubMed ID: 15872360
    [Abstract] [Full Text] [Related]

  • 9. Radioimmunotherapy of Metastatic Prostate Cancer with ¹⁷⁷Lu-DOTAhuJ591 Anti Prostate Specific Membrane Antigen Specific Monoclonal Antibody.
    Vallabhajosula S, Nikolopoulou A, Jhanwar YS, Kaur G, Tagawa ST, Nanus DM, Bander NH, Goldsmith SJ.
    Curr Radiopharm; 2016 May 15; 9(1):44-53. PubMed ID: 25771365
    [Abstract] [Full Text] [Related]

  • 10. Pharmacokinetics and biodistribution of 111In- and 177Lu-labeled J591 antibody specific for prostate-specific membrane antigen: prediction of 90Y-J591 radiation dosimetry based on 111In or 177Lu?
    Vallabhajosula S, Kuji I, Hamacher KA, Konishi S, Kostakoglu L, Kothari PA, Milowski MI, Nanus DM, Bander NH, Goldsmith SJ.
    J Nucl Med; 2005 Apr 15; 46(4):634-41. PubMed ID: 15809486
    [Abstract] [Full Text] [Related]

  • 11. Radioimmunotherapy of prostate cancer using 90Y- and 177Lu-labeled J591 monoclonal antibodies: effect of multiple treatments on myelotoxicity.
    Vallabhajosula S, Goldsmith SJ, Kostakoglu L, Milowsky MI, Nanus DM, Bander NH.
    Clin Cancer Res; 2005 Oct 01; 11(19 Pt 2):7195s-7200s. PubMed ID: 16203821
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer.
    Tagawa ST, Beltran H, Vallabhajosula S, Goldsmith SJ, Osborne J, Matulich D, Petrillo K, Parmar S, Nanus DM, Bander NH.
    Cancer; 2010 Feb 15; 116(4 Suppl):1075-83. PubMed ID: 20127956
    [Abstract] [Full Text] [Related]

  • 14. Biodistributions of 177Lu- and 111In-labeled 7E11 antibodies to prostate-specific membrane antigen in xenograft model of prostate cancer and potential use of 111In-7E11 as a pre-therapeutic agent for 177Lu-7E11 radioimmunotherapy.
    Pan MH, Gao DW, Feng J, He J, Seo Y, Tedesco J, Wolodzko JG, Hasegawa BH, Franc BL.
    Mol Imaging Biol; 2009 Feb 15; 11(3):159-66. PubMed ID: 19034582
    [Abstract] [Full Text] [Related]

  • 15. Prostate-Specific Membrane Antigen-Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of 225Ac-J591.
    Tagawa ST, Thomas C, Sartor AO, Sun M, Stangl-Kremser J, Bissassar M, Vallabhajosula S, Huicochea Castellanos S, Nauseef JT, Sternberg CN, Molina A, Ballman K, Nanus DM, Osborne JR, Bander NH.
    J Clin Oncol; 2024 Mar 01; 42(7):842-851. PubMed ID: 37922438
    [Abstract] [Full Text] [Related]

  • 16. Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors.
    Milowsky MI, Nanus DM, Kostakoglu L, Sheehan CE, Vallabhajosula S, Goldsmith SJ, Ross JS, Bander NH.
    J Clin Oncol; 2007 Feb 10; 25(5):540-7. PubMed ID: 17290063
    [Abstract] [Full Text] [Related]

  • 17. Phase I study of intravenous Lu-labeled CC49 murine monoclonal antibody in patients with advanced adenocarcinoma.
    Mulligan T, Carrasquillo JA, Chung Y, Milenic DE, Schlom J, Feuerstein I, Paik C, Perentesis P, Reynolds J, Curt G.
    Clin Cancer Res; 1995 Dec 10; 1(12):1447-54. PubMed ID: 9815943
    [Abstract] [Full Text] [Related]

  • 18. Phase I therapy study with (186)Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma.
    Börjesson PK, Postema EJ, Roos JC, Colnot DR, Marres HA, van Schie MH, Stehle G, de Bree R, Snow GB, Oyen WJ, van Dongen GA.
    Clin Cancer Res; 2003 Sep 01; 9(10 Pt 2):3961S-72S. PubMed ID: 14506195
    [Abstract] [Full Text] [Related]

  • 19. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.
    Rosenblum MG, Verschraegen CF, Murray JL, Kudelka AP, Gano J, Cheung L, Kavanagh JJ.
    Clin Cancer Res; 1999 May 01; 5(5):953-61. PubMed ID: 10353726
    [Abstract] [Full Text] [Related]

  • 20. Antibody mass escalation study in patients with castration-resistant prostate cancer using 111In-J591: lesion detectability and dosimetric projections for 90Y radioimmunotherapy.
    Pandit-Taskar N, O'Donoghue JA, Morris MJ, Wills EA, Schwartz LH, Gonen M, Scher HI, Larson SM, Divgi CR.
    J Nucl Med; 2008 Jul 01; 49(7):1066-74. PubMed ID: 18552139
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.